Published in Circulation on April 19, 2004
High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology (2009) 7.40
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest (2006) 4.50
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation (2008) 3.63
Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med (2011) 2.64
The tell-tale heart: population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarction. PLoS One (2007) 2.52
Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care (2007) 2.31
Aging is associated with reduced prostacyclin-mediated dilation in the human forearm. Hypertension (2009) 2.00
Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors. CMAJ (2006) 1.82
Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med (2006) 1.71
Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann Rheum Dis (2007) 1.68
Development and evaluation of a common data model enabling active drug safety surveillance using disparate healthcare databases. J Am Med Inform Assoc (2010) 1.62
Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. Crit Rev Oncol Hematol (2008) 1.42
Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ (2017) 1.40
Principles for evidence-based drug formulary policy. J Gen Intern Med (2005) 1.22
Cardiovascular co-morbidity in rheumatic diseases. Vasc Health Risk Manag (2008) 1.16
Multivariate-adjusted pharmacoepidemiologic analyses of confidential information pooled from multiple health care utilization databases. Pharmacoepidemiol Drug Saf (2010) 1.10
Validation of acute myocardial infarction in the Food and Drug Administration's Mini-Sentinel program. Pharmacoepidemiol Drug Saf (2012) 1.10
Prescriptions for chronic high-dose cyclooxygenase-2 inhibitors are often inappropriate and potentially dangerous. J Gen Intern Med (2005) 1.04
A review of gene-drug interactions for nonsteroidal anti-inflammatory drug use in preventing colorectal neoplasia. Pharmacogenomics J (2008) 1.04
Measuring population health using personal health messages. AMIA Annu Symp Proc (2009) 0.99
Risk of new acute myocardial infarction hospitalization associated with use of oral and parenteral non-steroidal anti-inflammation drugs (NSAIDs): a case-crossover study of Taiwan's National Health Insurance claims database and review of current evidence. BMC Cardiovasc Disord (2012) 0.98
Efficacy and safety of epicutaneous ketoprofen in Transfersome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: multicentre randomised controlled trial. Ann Rheum Dis (2007) 0.98
Design for validation of acute myocardial infarction cases in Mini-Sentinel. Pharmacoepidemiol Drug Saf (2012) 0.97
Cyclooxygenase-2 inhibitors and coronary occlusion--exploring dose-response relationships. Br J Clin Pharmacol (2006) 0.93
Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs. Br J Clin Pharmacol (2006) 0.93
The coxibs and traditional nonsteroidal anti-inflammatory drugs: a current perspective on cardiovascular risks. Can J Cardiol (2007) 0.92
Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice. Heart (2007) 0.92
Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities. Osteoarthritis Cartilage (2015) 0.91
The anti-cancer effect of COX-2 inhibitors on gastric cancer cells. Dig Dis Sci (2007) 0.91
Adjusted indirect comparison of celecoxib versus rofecoxib on cardiovascular risk. Rheumatol Int (2007) 0.87
Selective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice? Ther Clin Risk Manag (2007) 0.87
Reciprocal regulation of the nitric oxide and cyclooxygenase pathway in pathophysiology: relevance and clinical implications. Am J Physiol Regul Integr Comp Physiol (2013) 0.87
Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences? Naunyn Schmiedebergs Arch Pharmacol (2006) 0.83
The role of nitric oxide in prostaglandin biology; update. Nitric Oxide (2011) 0.83
The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction. Heart (2006) 0.83
Chemopreventive doses of resveratrol do not produce cardiotoxicity in a rodent model of hepatocellular carcinoma. Invest New Drugs (2009) 0.82
Study designs in paediatric pharmacoepidemiology. Eur J Clin Pharmacol (2010) 0.82
Comparison of preemptive analgesic effects of a single dose of nonopioid analgesics for pain management after ambulatory surgery: A prospective, randomized, single-blind studyin Turkish patients. Curr Ther Res Clin Exp (2005) 0.82
An economic model of long-term use of celecoxib in patients with osteoarthritis. BMC Gastroenterol (2007) 0.81
Gastroprotective strategies among NSAID users: guidelines for appropriate use in chronic illness. Can Fam Physician (2006) 0.80
Myocardial Infarction and Its Association with the Use of Nonselective NSAIDs: A Nested Case-Control and Time-to-Event Analysis. Perm J (2008) 0.79
A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment. Pharmacoepidemiol Drug Saf (2014) 0.79
Efficacy and Safety of COX-2 Inhibitors in the Clinical Management of Arthritis: Mini Review. ISRN Pharmacol (2011) 0.79
"Safe and effective when used as directed": the case of chronic use of opioid analgesics. J Med Toxicol (2012) 0.78
Effectiveness of polymer-coated extended-release morphine sulfate capsules in older patients with persistent moderate-to-severe pain: A subgroup analysis of a large, open-label, community-based trial. Curr Ther Res Clin Exp (2007) 0.78
Rofecoxib, but not celecoxib, increases the risk of thromboembolic cardiovascular events in young adults-a nationwide registry-based study. Eur J Clin Pharmacol (2010) 0.78
Celecoxib and sulfasalazine had negative association with coronary artery diseases in patients with ankylosing spondylitis: A nation-wide, population-based case-control study. Medicine (Baltimore) (2016) 0.77
Impact of maternal dexamethasone on coronary PGE(2) production and prostaglandin-dependent coronary reactivity. Am J Physiol Regul Integr Comp Physiol (2012) 0.77
Dimension reduction and shrinkage methods for high dimensional disease risk scores in historical data. Emerg Themes Epidemiol (2016) 0.77
A cohort study to evaluate cardiovascular risk of selective and nonselective cyclooxygenase inhibitors (COX-Is) in arthritic patients attending orthopedic department of a tertiary care hospital. Niger Med J (2014) 0.77
Modeling the binding modes of stilbene analogs to cyclooxygenase-2: a molecular docking study. J Mol Model (2010) 0.77
Model-based prediction of the acute and long-term safety profile of naproxen in rats. Br J Pharmacol (2015) 0.77
NMI-1182, a gastro-protective cyclo-oxygenase-inhibiting nitric oxide donor. Inflammopharmacology (2005) 0.77
Ten lessons to be learned from the withdrawal of Vioxx (rofecoxib). Eur J Epidemiol (2005) 0.76
Adverse drug reactions monitoring: prospects and impending challenges for pharmacovigilance. Springerplus (2014) 0.75
Efficacy and safety of short-term use of COX-2 inhibitors in patients after an acute stroke with musculoskeletal pain. Ann Indian Acad Neurol (2013) 0.75
Cyclooxygenase-2 Inhibition Limits Angiotensin II-Induced DNA Oxidation and Protein Nitration in Humans. Front Physiol (2017) 0.75
Coxibs and cardiovascular risk. CMAJ (2005) 0.75
Naproxen aggravates doxorubicin-induced cardiomyopathy in rats. Indian J Pharmacol (2010) 0.75
Rofecoxib use increases acute myocardial infarction risk. Circulation (2004) 0.75
Regular use of traditional analgesics predicts major coronary events: A cohort study. Ther Clin Risk Manag (2009) 0.75
Cardiovascular safety of celecoxib in acute myocardial infarction patients: a nested case-control study. Heart Int (2009) 0.75
Ischemic Colitis as a Complication of Medication Use: An Analysis of the Federal Adverse Event Reporting System. Dig Dis Sci (2016) 0.75
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
Variable selection for propensity score models. Am J Epidemiol (2006) 10.68
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet (2009) 10.52
A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol (2005) 8.77
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.65
Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med (2005) 8.44
Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 8.32
High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology (2009) 7.40
A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol (2005) 7.31
Long-term persistence in use of statin therapy in elderly patients. JAMA (2002) 7.19
Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J (2004) 6.57
Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol (2005) 6.20
A randomized study of how physicians interpret research funding disclosures. N Engl J Med (2012) 5.47
Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2012) 5.25
Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 5.13
Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med (2014) 4.99
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol (2003) 4.95
Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA (2011) 4.73
Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol (2006) 4.70
Self-management education programs in chronic disease: a systematic review and methodological critique of the literature. Arch Intern Med (2004) 4.68
Full coverage for preventive medications after myocardial infarction. N Engl J Med (2011) 4.51
The comparative safety of analgesics in older adults with arthritis. Arch Intern Med (2010) 4.47
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet (2012) 4.46
Multivitamins in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2012) 4.40
New FDA breakthrough-drug category--implications for patients. N Engl J Med (2014) 4.30
Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst (2002) 4.16
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet (2010) 4.07
Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med (2002) 4.07
Depression and risk of sudden cardiac death and coronary heart disease in women: results from the Nurses' Health Study. J Am Coll Cardiol (2009) 3.99
A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol (2011) 3.98
Use of antidepressants near delivery and risk of postpartum hemorrhage: cohort study of low income women in the United States. BMJ (2013) 3.88
Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA (2010) 3.85
Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol (2007) 3.82
The epidemiology of prescriptions abandoned at the pharmacy. Ann Intern Med (2010) 3.78
The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med (2006) 3.64
Burden of changes in pill appearance for patients receiving generic cardiovascular medications after myocardial infarction: cohort and nested case-control studies. Ann Intern Med (2014) 3.62
Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology (2006) 3.54
Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison. BMJ (2013) 3.43
The quality of pharmacologic care for vulnerable older patients. Ann Intern Med (2004) 3.34
Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol (2005) 3.33
The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med (2011) 3.27
Rethinking the use of physicians as hired expert lecturers. Ann Intern Med (2014) 3.22
Blood pressure and risk of developing type 2 diabetes mellitus: the Women's Health Study. Eur Heart J (2007) 3.21
Drug-review deadlines and safety problems. N Engl J Med (2008) 3.16
Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. JAMA Intern Med (2013) 3.13
Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation (2009) 3.09
Balancing innovation, access, and profits--market exclusivity for biologics. N Engl J Med (2009) 3.08
Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum (2006) 3.04
High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation (2013) 3.03
Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA (2011) 3.02
Confounding control in healthcare database research: challenges and potential approaches. Med Care (2010) 3.01
University-based science and biotechnology products: defining the boundaries of intellectual property. JAMA (2005) 2.95
Compliance with osteoporosis medications. Arch Intern Med (2005) 2.91
Hetastarch and bleeding complications after coronary artery surgery. Chest (2003) 2.87
Noncompliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors. J Gen Intern Med (2002) 2.85
Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med (2002) 2.82
Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. J Clin Epidemiol (2006) 2.81
Internet marketing of herbal products. JAMA (2003) 2.77
Economic implications of evidence-based prescribing for hypertension: can better care cost less? JAMA (2004) 2.77
Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study. Am J Epidemiol (2010) 2.74